Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 216

1.

Questionnaire survey evaluating disease-related knowledge for 149 primary gout patients and 184 doctors in South China.

Li QH, Dai L, Li ZX, Liu HJ, Zou CJ, Ou-Yang X, Lu M, Li T, Li YH, Mo YQ, Schumacher HR.

Clin Rheumatol. 2013 Nov;32(11):1633-40. doi: 10.1007/s10067-013-2333-0. Epub 2013 Jul 16.

PMID:
23857664
2.

A survey of current prescribing practices of antiinflammatory and urate-lowering drugs in gouty arthritis.

Stuart RA, Gow PJ, Bellamy N, Campbell J, Grigor R.

N Z Med J. 1991 Mar 27;104(908):115-7.

PMID:
2011292
3.

Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout.

Dalbeth N, House ME, Horne A, Petrie KJ, McQueen FM, Taylor WJ.

BMC Musculoskelet Disord. 2012 Sep 16;13:174. doi: 10.1186/1471-2474-13-174.

4.

Improving the use of allopurinol in chronic gout: monitoring oxypurinol levels to guide therapy.

Keith MP, Gilliland WR.

Clin Pharmacol Ther. 2011 Sep;90(3):363-4. doi: 10.1038/clpt.2011.146.

PMID:
21862966
5.

The management of gout at an academic healthcare center in Beijing: a physician survey.

Fang W, Zeng X, Li M, Chen LX, Schumacher HR Jr, Zhang F.

J Rheumatol. 2006 Oct;33(10):2041-9.

PMID:
17014019
6.

Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat.

Hatoum H, Khanna D, Lin SJ, Akhras KS, Shiozawa A, Khanna P.

Postgrad Med. 2014 Mar;126(2):65-75. doi: 10.3810/pgm.2014.03.2741.

PMID:
24685969
7.

Adherence to the 2012 American College of Rheumatology (ACR) Guidelines for Management of Gout: A Survey of Brazilian Rheumatologists.

Vargas-Santos AB, Castelar-Pinheiro Gda R, Coutinho ES, Schumacher HR Jr, Singh JA, Schlesinger N.

PLoS One. 2015 Aug 14;10(8):e0135805. doi: 10.1371/journal.pone.0135805. eCollection 2015.

8.

Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.

Becker MA, Schumacher HR, MacDonald PA, Lloyd E, Lademacher C.

J Rheumatol. 2009 Jun;36(6):1273-82. doi: 10.3899/jrheum.080814. Epub 2009 Mar 13.

PMID:
19286847
9.

Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.

Chohan S, Becker MA, MacDonald PA, Chefo S, Jackson RL.

Arthritis Care Res (Hoboken). 2012 Feb;64(2):256-61. doi: 10.1002/acr.20680.

10.

Efficacy and safety of a urate lowering regimen in primary gout.

Bailén R, González Senac NM, López MM, Llena ML, Migoya M, Rodríguez MT, de Miguel E, Torres RJ, Puig JG.

Nucleosides Nucleotides Nucleic Acids. 2014;33(4-6):174-80. doi: 10.1080/15257770.2013.853786.

PMID:
24940666
11.

Does starting allopurinol prolong acute treated gout? A randomized clinical trial.

Hill EM, Sky K, Sit M, Collamer A, Higgs J.

J Clin Rheumatol. 2015 Apr;21(3):120-5. doi: 10.1097/RHU.0000000000000235.

PMID:
25807090
12.

Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout.

Feher MD, Hepburn AL, Hogarth MB, Ball SG, Kaye SA.

Rheumatology (Oxford). 2003 Feb;42(2):321-5.

PMID:
12595630
13.

The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age.

Jackson RL, Hunt B, MacDonald PA.

BMC Geriatr. 2012 Mar 21;12:11. doi: 10.1186/1471-2318-12-11.

14.

Significance of the initiation time of urate-lowering therapy in gout patients: A retrospective research.

Feng X, Li Y, Gao W.

Joint Bone Spine. 2015 Dec;82(6):428-31. doi: 10.1016/j.jbspin.2015.02.021. Epub 2015 Oct 9.

PMID:
26456042
15.
16.

Comprehensive dietary education in treated gout patients does not further improve serum urate.

Holland R, McGill NW.

Intern Med J. 2015 Feb;45(2):189-94. doi: 10.1111/imj.12661.

PMID:
25495503
17.

Monitoring of Urate-Lowering Therapy Among US Veterans Following the 2012 American College of Rheumatology Guidelines for Management of Gout.

Hughes JC, Wallace JL, Bryant CL, Salvig BE, Fourakre TN, Stone WJ.

Ann Pharmacother. 2017 Apr;51(4):301-306. doi: 10.1177/1060028016679848. Epub 2016 Nov 24.

PMID:
27881692
18.

Physician adherence to ACR gout treatment guidelines: perception versus practice.

Oderda GM, Shiozawa A, Walsh M, Hess K, Brixner DI, Feehan M, Akhras K.

Postgrad Med. 2014 May;126(3):257-67. doi: 10.3810/pgm.2014.05.2774.

PMID:
24918810
19.

Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.

Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, Lademacher C, Joseph-Ridge N.

Arthritis Rheum. 2008 Nov 15;59(11):1540-8. doi: 10.1002/art.24209.

20.

Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials.

Wortmann RL, Macdonald PA, Hunt B, Jackson RL.

Clin Ther. 2010 Dec;32(14):2386-97. doi: 10.1016/j.clinthera.2011.01.008.

PMID:
21353107

Supplemental Content

Support Center